PH response type injectable hydrogel loaded with prNK-lysin as well as preparation method and application of pH response type injectable hydrogel
By designing a pH-responsive injectable hydrogel loaded with prNK-lysin, the pH-responsive Schiff alkali bond is used to achieve controllable release, solving the problem of delivery and stability of protein drugs in the body, and significantly inhibiting the tumors of dog breasts Growth and transfer improve the therapeutic effect.
Patent Information
- Application Number
- CN202411140013.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-20
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively deliver the protein drug prNK-lysin to the tumor area, resulting in the failure to fully realize its anti-tumor potential in the body. Moreover, protein drugs are prone to hydrolysis and degeneration after systemic administration, with short circulation time and poor penetration. Influencing the treatment effect.
Using pH-responsive injectable hydrogels loaded with prNK-lysin, designed by oxidizing dextran and aminated hyaluronic acid, prNK-lysin is encapsulated in the hydrogel by physical embedding, and using pH response The Sex Schiff alkali bond achieves controllable release, improving drug accumulation and therapeutic effect in the tumor area.
The effective delivery and sustained release of prNK-lysin is achieved, which significantly inhibits the growth and metastasis of tumor cells in dog breasts, improves the therapeutic effect, avoids explosive release of drugs, and ensures high enrichment of drugs in tumor tissues and biological Compatibility.
Smart Images

Figure CN118986859A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of clinical veterinary medicine and biochemical materials, and in particular to a pH-responsive injectable hydrogel loaded with prNK-lysin, and a preparation method and application thereof. Background Art
[0002] Canine mammary tumors (CMT) are the leading cause of death in female dogs, with an incidence rate three times that of humans. More than 50% of cases are malignant, and 50% of malignant CMTs have metastasized. CMT has similarities with human breast cancer in clinical pathological characteristics and pathogenesis, such as age of onset, metastatic spread, and many molecular markers and genetic risk factors. Research on CMT not only protects the health and welfare of dogs, but also provides reference for the clinical treatment of human breast tumors. Treatment options for CMT include surgical resection, chemotherapy, and radiotherapy. However, these treatments still have certain limitations. Surgical resection involves removal of cancerous glands and local lymph nodes. However, surgery alone cannot cure all dogs due to high rates of metastasis and recurrence. In addition, small molecule chemotherapy drugs often cause damage to normal cells and tissues of the body and are prone to drug resistance. Based on the limitations of these treatment methods, the industry is actively exploring and developing new therapeutic drugs or treatment methods to improve the treatment effect of CMT.
[0003] Protein drugs play an important role in the treatment, diagnosis and prevention of diseases. Compared with small molecule chemotherapy drugs, protein drugs have higher therapeutic specificity and biological activity, less toxic side effects on normal cells, and lower risk of gene mutation. So far, many proteins have shown good anticancer activity and have been used in clinical treatment of tumors. prNK-lysin belongs to the saponin-like protein family (SAPLIP) and is a 9-kDa cationic protein produced by porcine natural killer (NK) cells and cytotoxic T lymphocytes (CTLs). It is activated and synthesized under the stimulation of antigens and cytokines. prNK-lysin has a wide range of antibacterial, antiparasitic and anti-inflammatory activities. prNK-lysin and its derivatives have also been found to kill a variety of tumor cells. Our research team has previously demonstrated that prNK-lysin has the ability to inhibit the proliferation, invasion and metastasis of liver cancer cells in vitro and is harmless to red blood cells. However, how to fully exert the anti-tumor potential of prNK-lysin in vivo still faces great challenges. Proteins are prone to hydrolysis and denaturation after systemic administration, have short circulation times, and have poor penetration into tumor tissues. The clinical translation of protein-based tumor treatments is hampered by various problems.
[0004] Considering the application prospects of prNK-lysin in breast cancer treatment, it is important to develop a reasonable and effective drug delivery strategy. This will require drug carriers to maintain or increase their biological activity while maximizing the delivery of prNK-lysin to the tumor area. In recent years, injectable hydrogels have rapidly developed into a new drug delivery system with biosafety and sustained release, simple operation and low invasiveness. Through intratumoral administration, it improves its tumor accumulation and avoids the nonspecific distribution of drugs in healthy organs. Therefore, it has been widely studied and applied to the treatment of tumors. The hydrophilic characteristics of hydrogels provide a biomimetic moist environment for biomacromolecules, which is conducive to maintaining their biological activity and is suitable as a delivery platform for protein drugs. Previous reports have shown that local treatment of hydrogel-encapsulated protein drugs shows better breast tumor growth inhibition compared with local or systemic delivery of non-encapsulated protein drugs. In addition, smart hydrogels that have been specifically and functionally modified can sense changes in the external environment or stimuli, change the corresponding physical structure and chemical properties, and further allow the release of proteins "on demand" at the tumor site. However, since the current research on injectable hydrogels is mainly based on the intratumoral gelation of soluble precursors, the complex physiological environment may delay or hinder the sol-gel transformation, resulting in explosive drug release and unpredictable pharmacokinetics, which in turn affects the therapeutic effect. Therefore, it is still challenging to prepare an ideal hydrogel delivery carrier to solve these problems in order to achieve effective protein drug encapsulation, delivery and release. Summary of the invention
[0005] The purpose of the present invention is to provide a pH-responsive injectable hydrogel loaded with prNK-lysin and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art.
[0006] To achieve the above object, the present invention provides the following solutions:
[0007] One of the technical solutions of the present invention is a method for preparing a pH-responsive injectable hydrogel loaded with prNK-lysin, comprising the following steps:
[0008] (1) adding sodium periodate (NaIO4) to a dextran (DEX) solution to carry out an oxidation reaction, and dialyzing to obtain oxidized dextran (ODEX) after the reaction is completed; then adding ethylenediamine to carry out a Schiff base reaction, and dialyzing and freeze-drying to obtain a DEX / Schiff base bond after the reaction is completed;
[0009] (2) Dextran (DEX) and carbonyldiimidazole (CDI) are dissolved in dimethyl sulfoxide (DMSO) for the first reaction. After the reaction is completed, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) are added for the second reaction, and then amino hyaluronic acid (NH2-PEG-HA) is added for the third reaction. Finally, DEX / HA is obtained by dialysis and freeze-drying.
[0010] (3) DEX / Schiff base bond and DEX / HA are mixed and stirred to react to obtain DEX / HA Gel; prNK-lysin is encapsulated in DEX / HA Gel by a physical embedding method to obtain the pH-responsive injectable hydrogel prNK-lysin@DEX / HA Gel loaded with prNK-lysin.
[0011] The second technical solution of the present invention is the pH-responsive injectable hydrogel prNK-lysin@DEX / HA Gel loaded with prNK-lysin prepared by the preparation method.
[0012] The third technical solution of the present invention is the use of the pH-responsive injectable hydrogel prNK-lysin@DEX / HAGel loaded with prNK-lysin in the preparation of drugs for treating canine mammary tumors.
[0013] The fourth technical solution of the present invention is a drug for treating canine mammary tumors, comprising the pH-responsive injectable hydrogel prNK-lysin@DEX / HAGel loaded with prNK-lysin.
[0014] Based on the above technical solution, the present invention has the following technical effects:
[0015] 1. This invention is the first to use an in situ delivery strategy to deliver prNK-lysin to canine mammary tumor cells, thereby effectively inhibiting the growth and metastasis of canine mammary tumor cells, providing new insights into the clinical treatment of canine mammary tumors.
[0016] 2. The hydrogel has pH-responsive Schiff base bonds, thus having controllable sustained-release properties of prNK-lysin.
[0017] 3. The hydrogel carrier has a low storage modulus (G') and soft physical properties, which can be easily injected into tumor tissue and avoid the explosive release of prNK-lysin.
[0018] 4. Aminated hyaluronic acid (NH2-PEG-HA) is coupled to the hydrogel material to enable it to specifically bind to the surface receptors of canine mammary tumor cells, thereby increasing the enrichment of the hydrogel material in the tumor tissue.
[0019] 5. The hydrogel carrier has good biocompatibility.
[0020] 6. prNK-lysin@DEX / HA can effectively inhibit the proliferation, migration and invasion of canine mammary tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0022] Figure 1 The external morphology of the hydrogel is observed, where A shows the injectability of the hydrogel carrier, and B shows the viscosity of the hydrogel carrier.
[0023] Figure 2 This is the SEM observation of hydrogel, where A is 1 mm and B is 100 μm.
[0024] Figure 3 FTIR spectrum of DEX hydrogel.
[0025] Figure 4 It is a test of the rheological properties of hydrogels, wherein A is the variation characteristics of the storage modulus (G′) of hydrogels at different pH levels with angular frequency, and B is the variation characteristics of the loss modulus (G″) of hydrogels at different pH levels with angular frequency.
[0026] Figure 5 This is the drug release curve of the hydrogel carrier.
[0027] Figure 6 In vitro degradation of hydrogels.
[0028] Figure 7 SEM observations of hydrogels under different pH conditions, where A is under pH 5.5, B is under pH 6.5, and C is under pH 7.4.
[0029] Figure 8 Coagulation experiment of hydrogel.
[0030] Fig. 9 To evaluate the safety of hydrogel solution on canine mammary epithelial cells.
[0031] Fig.10 The proliferation cell density of canine mammary epithelial cells at different time points.
[0032] Fig.11The effect of prNK-lysin@DEX / HA on the proliferation activity of CHMm cells at 24h (A) and 48h (B).
[0033] Fig.12 The effect of prNK-lysin@DEX / HA on the proliferation activity of CHMp cells at 24h (A) and 48h (B).
[0034] Fig.13 This is the effect of prNK-lysin@DEX / HA on the migration ability of CHMm cells.
[0035] Fig.14 is the healing rate of CHMm cells.
[0036] Fig.15 This is the effect of prNK-lysin@DEX / HA on the migration ability of CHMp cells.
[0037] Fig.16 is the healing rate of CHMp cells.
[0038] Fig.17 This is the effect of prNK-lysin@DEX / HA on the invasion ability of CHMm cells.
[0039] Fig.18 is the number of CHMm invading cells.
[0040] Fig.19 This is the effect of prNK-lysin@DEX / HA on the invasion ability of CHMp cells.
[0041] Fig. 20 is the number of CHMp invading cells.
[0042] Fig.21 Cellular uptake experiment of drug-loaded hydrogel at different time points. DETAILED DESCRIPTION
[0043] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0044] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0045] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0046] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.
[0047] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0048] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.
[0049] The embodiment of the present invention provides a method for preparing a pH-responsive injectable hydrogel loaded with prNK-lysin, comprising the following steps:
[0050] (1) adding sodium periodate (NaIO4) to a dextran (DEX) solution to carry out an oxidation reaction, and dialyzing to obtain oxidized dextran (ODEX) after the reaction is completed; then adding ethylenediamine to carry out a Schiff base reaction, and dialyzing and freeze-drying to obtain a DEX / Schiff base bond after the reaction is completed;
[0051] (2) Dextran (DEX) and carbonyldiimidazole (CDI) were dissolved in dimethyl sulfoxide (DMSO) for the first reaction. After the reaction was completed, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) were added for the second reaction. Aminated hyaluronic acid (NH2-PEG-HA) was added for the third reaction. Finally, DEX / HA was obtained by dialysis and freeze-drying.
[0052] (3) DEX / Schiff base bond and DEX / HA are mixed and stirred to react to obtain DEX / HA Gel; prNK-lysin is encapsulated in DEX / HA Gel by a physical embedding method to obtain the pH-responsive injectable hydrogel prNK-lysin@DEX / HA Gel loaded with prNK-lysin.
[0053] In some specific embodiments, in step (1), the mass volume ratio of dextran, sodium periodate and ethylenediamine is (5-10) g: (1-2) g: (10-20) mL.
[0054] In some specific embodiments, in step (1), the oxidation reaction time is 6-12 hours; the reaction temperature of the Schiff base reaction is 37-42° C., and the reaction time is 6-8 hours.
[0055] In some specific embodiments, in step (2), the mass ratio of dextran, CDI, EDC, NHS and amino hyaluronic acid is (5-10):(1-2):(3-6):(3.5-7):(3-6).
[0056] In some specific embodiments, in step (2), the conditions of the first reaction are: reaction in a nitrogen atmosphere, the temperature is 50-60°C, and the time is 40-90 min; the conditions of the second reaction are: shaking reaction, the temperature is 37°C, the rotation speed is 150-250 rpm, and the time is 30-60 min; the conditions of the third reaction are: shaking reaction, the temperature is 37°C, the rotation speed is 150-250 rpm, and the time is 12-24 h.
[0057] In some specific embodiments, in step (3), the volume ratio of DEX / Schiff base bond and DEX / HA is 4:1; and the stirring reaction time is 5-12 hours.
[0058] Based on the characteristics of tumor tissue microenvironment, the present invention designs a pH-responsive hydrogel drug delivery system in order to enhance the inhibitory effect of prNK-lysin on the growth and metastasis of canine mammary tumor cells.
[0059] (1) The hydrogel has a low storage modulus (G') and soft physical properties, and can be easily injected into tumor tissue. (2) Hyaluronic acid is coupled to the oxidized dextran skeleton, allowing it to specifically bind to tumor cell surface receptors, thereby increasing the enrichment of the hydrogel material in tumor tissue. (3) In the microenvironment of tumor tissue, the pH-responsive Schiff base bonds break, causing the hydrogel network structure to be destroyed and collapsed, thereby releasing the embedded prNK-lysin. (4) The hydrogel material has good biocompatibility. (5) prNK-lysin@DEX / HAGel can effectively inhibit the proliferation, migration and invasion of canine mammary tumor cells.
[0060] The embodiment of the present invention also provides a pH-responsive injectable hydrogel prNK-lysin@DEX / HA Gel loaded with prNK-lysin prepared by the preparation method.
[0061] The embodiment of the present invention also provides the use of the pH-responsive injectable hydrogel prNK-lysin@DEX / HAGel loaded with prNK-lysin in the preparation of a drug for treating canine mammary tumors.
[0062] In the embodiment of the present invention, prNK-lysin was prepared by the Shanxi Provincial Key Laboratory of Modernization of Traditional Chinese Veterinary Medicine of Shanxi Agricultural University. For details, see (1) Khan Ajab, Fan KH, Sun N, et al. Recombinant porcine prNK-lysin inhibits the invasion of hepatocellular carcinoma cells in vitro [J]. International Journal of Biological Macromolecules, 2019 (140): 1249-1259. (2) Fan KH, Du WJ, Wang ZR, et al. Anti-Invasion and Antimetastatic Effects of Porcine Recombinant prNK-lysin on SMMC-7721 Human Hepatocellular Carcinoma Cells [J]. BioMed Research International, 2019: e5318729. (3) Kuo hai Fan, Hong quan Li, Zhi rui Wang, Wenjuan Du, Wei Yin, Yao gui Sun, Jun bing Jiang. Expression andPurification of the Recombinant Porcine NK-lysin in Pichia pastoris andObservation of Anticancer Activity in Vitro[J].Preparative BiochemistryandBiotechnology, 2015,46(1):65-70.
[0063] Example 1
[0064] prNK-lysin@DEX / HAGel is a pH-sensitive smart hydrogel that can be used as a sustained and controllable in situ drug release carrier. Dextran (DEX) is used as the hydrogel skeleton material, which has good biocompatibility and water solubility and can be functionalized through active hydroxyl groups.
[0065] The preparation method comprises the following steps:
[0066] First, sodium periodate (NaIO4) was used to oxidize dextran (DEX) with multiple hydroxyl groups to form oxidized dextran (ODEX) with aldehyde groups at the ends: 0.5 g of DEX was dissolved in deionized water and stirred until clear and transparent, 100 mg of NaIO4 was added for oxidation, and the mixture was stirred for 6 h to obtain aldehyde groups, which were then dialyzed to obtain ODEX; 1 mL of ethylenediamine was added, and after stirring at 37°C for 6 to 8 hours, the aldehyde groups of the ODEX gel reacted with the amino groups at both ends of the ethylenediamine to undergo a Schiff base reaction, thereby introducing a pH-sensitive imine bond, which was dialyzed and freeze-dried to obtain 1st gel (DEX / Schiff base bond).
[0067] Then, the hydroxyl groups on the DEX molecules were oxidized to carboxyl groups: 0.5 g of dextran (DEX) and 100 mg of carbonyldiimidazole (CDI) were dissolved in 20 mL of dimethyl sulfoxide (DMSO), and reacted at 50°C with nitrogen for 40 min to form carboxyl groups; 300 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 350 mg of N-hydroxysuccinimide (NHS) were added to activate the carboxyl groups, and the reaction was carried out at 37°C on a shaker at 250 rpm for 30 min; 0.3 g of amino hyaluronic acid (NH2-PEG-HA) was added, and the reaction was carried out at 37°C on a shaker at 250 rpm for 12 h. The carboxyl groups on the DEX molecules reacted with the amino groups on the NH2-PEG-HA molecules to form amide bonds. After dialysis treatment and freeze-drying, 2st gel (DEX / HA) was obtained.
[0068] The 1st gel and the 2st gel were mixed at a volume ratio of 4:1 and stirred for 5 hours to prepare the final pH-sensitive hydrogel DEX / HAGel. Finally, prNK-lysin was encapsulated in DEX / HAGel by physical encapsulation to obtain prNK-lysin@DEX / HA Gel.
[0069] Example 2
[0070] 1. Characterization of prNK-lysin@DEX / HAGel
[0071] 1.1 Observation of hydrogel external morphology Figure 1As shown, the synthesized hydrogel has a large viscosity, which can effectively integrate prNK-lysin into the gel matrix, increasing its efficacy as a sustained, controlled drug release carrier. The injected hydrogel can be stretched like a rubber band, and these soft material properties represent its good injectability. Moreover, gelation before injection can maintain the integrity of the hydrogel structure and prevent the soluble gel precursor and protein drugs from leaking into the surrounding tissue.
[0072] 1.2 Scanning electron microscopy (SEM) was used to characterize the internal morphology of the freeze-dried hydrogel. SEM detection found that DEX / HAGel has a clear three-dimensional network structure ( Figure 2 ). Its loose, porous and interconnected structure is conducive to the subsequent controlled release of prNK-lysin.
[0073] 1.3 FT-IR spectra of dextran (DEX) and DEX / HA Gel Figure 3 The similar spectra of dextran and DEX / HAGel indicate that they have similar chemical structures. Compared with Dextran, DEX / HAGel has a -1 There is a FT-IR characteristic vibration at 1480 cm -1 The characteristic absorption peak of C=N at 1650 cm-1 was found, confirming the existence of Schiff base bonds and indicating that the synthesized hydrogel was pH sensitive. -1 The characteristic absorption peak of CONH was enhanced, indicating that NH2-PEG-HA was coupled to the hydrogel dextran backbone through amide reaction to obtain DEX / HA.
[0074] 1.4 The gelation behavior of prNK-lysin@DEX / HA Gel was evaluated by oscillatory rheological experiments, mainly monitoring the changes of storage modulus (G′) and loss modulus (G″) with angular frequency at room temperature under different pH conditions. The storage modulus, also known as the elastic modulus, mainly verifies the elasticity of the hydrogel; the loss modulus, also known as the viscous modulus, is mainly used to characterize the viscosity of the hydrogel. The differences in storage modulus and loss modulus of different hydrogels are attributed to their degree of crosslinking. The results are shown in Figure 1. Figure 4As shown in the figure, under pH 7.4, the G′ value of the hydrogel is as low as 61.3Pa, and the G′ value is close to the G″ value, indicating that the hydrogel is a soft hydrogel with viscosity. Studies have shown that the activity of protein drugs can be well maintained in soft hydrogels. Compared with traditional hard hydrogels, soft hydrogels are conducive to the release of protein drugs and have better tumor inhibition effects. In addition, as the pH value changes from neutral to acidic, the G′ value of the hydrogel decreases rapidly, and the G′ value is slightly lower than the G″ value, indicating that under acidic conditions, the elasticity of the hydrogel decreases and the fluidity increases, which may be related to the pH responsiveness of the hydrogel.
[0075] 2. In vitro drug release experiment
[0076] The in vitro release efficiency of prNK-lysin in the hydrogel was quantitatively evaluated by simulating the tumor microenvironment, i.e., in an acidic solution at 37°C. Figure 5 As shown in the figure, in the solution of pH 7.4, the release rate of prNK-lysin was relatively low, while in the solution of pH 6.5 and 5.5, the cumulative release of prNK-lysin increased significantly. The calculation results showed that after 48h of incubation, the release rates of prNK-lysin were 46.2% (pH 7.4), 61.8% (pH 6.5) and 70.8% (pH 5.5), respectively. The results showed that prNK-lysin@DEX / HAGel exhibited pH-dependent drug release kinetics, which may be due to the breakage of pH-sensitive Schiff base bonds and the collapse of the hydrogel network structure in an acidic environment, which promoted the release of the drug. In addition, prNK-lysin showed a sustained release process within 48 hours, indicating that the hydrogel can be used as a sustained and controllable in situ drug release carrier.
[0077] 3. In vitro degradation test
[0078] To further demonstrate the in vitro degradation performance of the hydrogel, DEX / HAGel was freeze-dried to prepare dry samples, and their in vitro biodegradation was monitored in PBS solutions with pH values of 7.4, 6.5, and 5.5 at 37°C. Figure 6 As shown in the figure, after immersion for 24 hours, the hydrogel incubated in an acidic environment degraded rapidly, especially in a solution of pH 5.5; in contrast, slow degradation of the hydrogel was observed in a PBS solution of pH 7.4, maintaining most of its integrity, indicating that in the absence of acidic stimulation, the hydrogel has a relatively stable structure, which is necessary to control drug release to avoid side effects on normal tissues. Similarly, the hydrogel was incubated in PBS solutions of different pH values and then freeze-dried, and the changes in its internal morphology and structure were observed under SEM images. Figure 7As shown in the figure, the pore size of the hydrogel becomes larger and the network structure collapses in an acidic environment. The reason for these phenomena may be that in an acidic environment, the Schiff base bonds in the hydrogel break and accelerate the biodegradation of the hydrogel. In addition, under physiological conditions, dextran is easily degraded by dextranase in the human colon, which means that the hydrogel carrier with dextran as the skeleton will not accumulate in the body and will not cause unexpected adverse reactions. In short, this pH responsiveness and good biodegradability become the basis for the in vivo application of hydrogel carriers.
[0079] 4. In vitro safety evaluation experiment
[0080] 4.1 The blood compatibility of the hydrogel was evaluated by hemolysis test. Distilled water as the positive control was bright red, while the negative control PBS and different concentrations of DEX / HA hydrogel solutions were transparent. Figure 8 As shown, the hemolysis rates of 20, 40, 60, 80 and 100 mg / mLDEX / HAGel solutions were 0.24%, -0.03%, 0.12%, 0.08% and 0.22%, respectively, and the hemolytic ability was negligible (less than 5%), indicating that the hydrogel carrier has excellent blood compatibility in biological applications.
[0081] 4.2 CCK-8 assay was performed on DEX / HA hydrogel solutions of different concentrations to evaluate their biocompatibility. Fig. 9 As shown, regardless of the concentration difference, at 24h, 48h and 72h, the DEX / HA hydrogel solution had almost no toxicity to canine mammary epithelial cells, and the cell survival rate was not significantly different from that of the control solution (P>0.05). In addition, as time increased, the quantitative determination of the CCK-8 test results showed that its absorbance continued to increase, indicating that canine mammary epithelial cells continued to proliferate in the hydrogel culture medium solution ( Fig.10 ), showing that the hydrogel has good biocompatibility, ensuring its safe application in vivo.
[0082] 5. Cytotoxicity assay
[0083] 5.1 The CCK-8 method was used to verify the effect of prNK-lysin@DEX / HAGel on the proliferation activity of canine mammary tumor cells (CHMm), and the in vitro cell compatibility of blank hydrogel DEX / HAGel was analyzed. Fig.11As shown, after 24h of incubation, when the concentration of prNK-lysin reached 80μg / ml, the proliferation inhibition rate of prNK-lysin@DEX / HA Gel on CHMm cells was 11%, and after 48h of incubation, its proliferation inhibition rate on CHMm cells reached 50%. The results showed that prNK-lysin@DEX / HAGel had a significant inhibitory effect on the viability of CHMm cells, and the degree of inhibition increased with the increase of prNK-lysin concentration and incubation time. At the same drug concentration, prNK-lysin had a stronger inhibitory effect on cell proliferation activity than prNK-lysin@DEX / HA Gel, which further confirmed the slow and sustained drug release characteristics of the hydrogel. In addition, after incubation of blank hydrogel DEX / HAGel in CHMm cells for 24h and 48h, the cell viability was greater than 88%, and there was no obvious cytopathic effect, indicating that the hydrogel material has good in vitro cell compatibility.
[0084] 5.2 The CCK-8 method was used to verify the effect of prNK-lysin@DEX / HAGel on the proliferation activity of canine mammary tumor cells (CHMp), and the in vitro cell compatibility of blank hydrogel DEX / HAGel was analyzed. Fig.12 As shown, after 24h of incubation, when the concentration of prNK-lysin reached 120μg / ml, the inhibition rate of prNK-lysin@DEX / HAGel on the proliferation of CHMp cells was 15%, and after 48h of incubation, its inhibition rate on the proliferation of CHMm cells reached 56%. The results showed that prNK-lysin@DEX / HAGel had a significant inhibitory effect on the viability of CHMp cells, and the degree of inhibition increased with the increase of prNK-lysin concentration and incubation time. At the same drug concentration, prNK-lysin had a stronger inhibitory effect on cell proliferation activity than prNK-lysin@DEX / HA Gel, which further confirmed the slow and sustained drug release characteristics of the hydrogel. In addition, after incubation of blank hydrogel DEX / HAGel in CHMp cells for 24h and 48h, the cell viability was greater than 89%, and there was no obvious cytopathic effect, indicating that the hydrogel material has good in vitro cell compatibility.
[0085] 6. Cell scratch test
[0086] 6.1 The cell scratch assay was used to verify the effects of prNK-lysin@DEX / HA Gel and DEX / HA Gel on the proliferation activity of canine mammary tumor cells (CHMm). Fig.13 , 14As shown in the figure, the wound area of the control group, PBS group and DEX / HA group was significantly restored after 24 hours, and the healing rate was greater than 50%. In contrast, the wound healing rates of CHMm cells treated with prNK-lysin and prNK-lysin@DEX / HA were only 24% and 36% after 24 hours, respectively. The results showed that the hydrogel can significantly inhibit the migration of CHMm cells by releasing prNK-lysin.
[0087] 6.2 The cell scratch assay was used to verify the effects of prNK-lysin@DEX / HA Gel and DEX / HA Gel on the proliferation activity of canine mammary tumor cells (CHMp). Fig.15 , 16 As shown in the figure, the wound area of the control group, PBS group and DEX / HA group was significantly restored after 24 hours, and the healing rate was close to 70%. In contrast, the wound healing rates of CHMp cells treated with prNK-lysin and prNK-lysin@DEX / HA were only 29% and 47% after 24 hours, respectively. The results showed that the hydrogel can significantly inhibit the migration of CHMp cells by releasing prNK-lysin.
[0088] 7. Cell invasion assay
[0089] 7.1 The effects of prNK-lysin@DEX / HA Gel and DEX / HA Gel on the invasion ability of CHMm cells were evaluated using Transwell chambers. Fig.17 , 18 As shown, compared with other control groups, the invasion ability of CHMm cells treated with prNK-lysin@DEX / HA Gel and free prNK-lysin (purple staining) was significantly reduced (field of view 200×).
[0090] 7.2 The effects of prNK-lysin@DEX / HA Gel and DEX / HA Gel on the invasion ability of CHMp cells were evaluated using Transwell chambers. Fig.19 , 20 As shown, compared with other control groups, the invasion ability of CHMp cells treated with prNK-lysin@DEX / HA Gel and free prNK-lysin (purple staining) was also significantly reduced (field of view 200×).
[0091] 8. Cellular uptake experiment
[0092] Confocal laser scanning microscopy was used to further observe the accumulation of prNK-lysin in CHMm cells. Fig.21As shown in the figure, CHMm cells treated with free prNK-lysin or prNK-lysin@DEX / HA Gel showed weak red fluorescence signals within 6 hours; CHMm cells treated with free prNK-lysin or prNK-lysin@DEX / HAGel showed obvious diffuse red fluorescence signals within 12 hours. The results showed that prNK-lysin released by prNK-lysin@DEX / HAGel can enter CHMm cells and play an anti-canine mammary tumor role; in addition, at different time points, the fluorescence intensity of CHMm cells treated with prNK-lysin@DEX / HA Gel was weaker than that of free prNK-lysin, which further confirmed the slow and sustained drug release characteristics of the hydrogel.
[0093] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.
Claims
1. A method for preparing a pH-responsive injectable hydrogel loaded with prNK-lysin, characterized in that: The following steps are involved: (1) adding sodium periodate to a dextran solution for oxidation reaction, and dialyzing after the reaction to obtain oxidized dextran; then adding ethylenediamine for Schiff base reaction, and dialyzing and freeze-drying after the reaction to obtain a DEX / Schiff base bond; (2) dissolving dextran and carbonyldiimidazole in dimethyl sulfoxide for a first reaction, adding 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and N-hydroxysuccinimide for a second reaction after the reaction is completed, and then adding amino hyaluronic acid for a third reaction, and finally dialyzing and freeze-drying to obtain DEX / HA; (3) DEX / Schiff base bond and DEX / HA are mixed and stirred to react to obtain DEX / HA Gel; prNK-lysin is encapsulated in DEX / HA Gel by a physical embedding method to obtain the pH-responsive injectable hydrogel prNK-lysin@DEX / HAGel.
2. The preparation method according to claim 1, characterized in that: In step (1), the mass volume ratio of dextran, sodium periodate and ethylenediamine is (5-10) g: (1-2) g: (10-20) mL.
3. The preparation method according to claim 1, characterized in that: In step (1), the oxidation reaction time is 6-12 hours; the reaction temperature of the Schiff base reaction is 37-42° C., and the reaction time is 6-8 hours.
4. The preparation method according to claim 1, characterized in that: In step (2), the mass ratio of dextran, CDI, EDC, NHS and amino hyaluronic acid is (5-10):(1-2):(3-6):(3.5-7):(3-6).
5. The preparation method according to claim 1, characterized in that: In step (2), the conditions of the first reaction are: reaction in a nitrogen atmosphere, the temperature is 50-60°C, and the time is 40-90 min; the conditions of the second reaction are: shaking reaction, the temperature is 37°C, the rotation speed is 150-250 rpm, and the time is 30-60 min; the conditions of the third reaction are: shaking reaction, the temperature is 37°C, the rotation speed is 150-250 rpm, and the time is 12-24 h.
6. The preparation method according to claim 1, characterized in that: In step (3), the volume ratio of DEX / Schiff base bond and DEX / HA is 4:1; and the stirring reaction time is 5-12 hours.
7. The pH-responsive injectable hydrogel prNK-lysin@DEX / HA Gel loaded with prNK-lysin prepared by the preparation method according to any one of claims 1 to 6.
8. Use of the pH-responsive injectable hydrogel prNK-lysin@DEX / HAGel loaded with prNK-lysin as claimed in claim 7 in the preparation of a drug for treating canine mammary tumors.
9. A drug for treating canine mammary tumors, characterized in that: The pH-responsive injectable hydrogel prNK-lysin@DEX / HA Gel loaded with prNK-lysin as described in claim 7.
